The content is available as a PDF (565.6 KB).
Footnotes
Conflicts of Interest: None
Financial Disclosure: None
Patient Consent Forms: Not applicable
editorial . 2023 Jun 28. Online ahead of print. doi: 10.1016/j.jaad.2023.06.034
Gaining Perspective on mRNA COVID-19 Vaccination Risk
Warren R Heymann
1,∗
Warren R Heymann, MD
1100 Brick Road – Suite 306, Marlton, New Jersey 08053
Find articles by Warren R Heymann
1100 Brick Road – Suite 306, Marlton, New Jersey 08053
∗
Corresponding author: 100 Brick Road – Suite 306, Marlton, New Jersey 08053 Phone 856-596-0111 Fax 856-596-7194
Received 2023 Jun 18; Accepted 2023 Jun 19.
Key Words: COVID-19, mRNA vaccine, autoimmune disease, collagen vascular disease
© 2023 Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC10299837 PMID: 37385451
See the article "Risk of autoimmune skin and connective tissue disorders after mRNA-based COVID-19 vaccination" on page null.